Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

COUCH Medcomms

- PMLiVE

Eli Lilly and Camurus enter cardiometabolic health partnership worth up to $870m

The deal gives Lilly exclusive global rights to incretin products based on Camurus’ technology

- PMLiVE

AstraZeneca’s Calquence approved by EC for first-line chronic lymphocytic leukaemia use

An estimated 27,000 cases of the disease were diagnosed in the UK, France, Germany, Spain and Italy in 2024

- PMLiVE

Conferences: the value of real experience versus virtual convenience

By Hannah Tivey

- PMLiVE

The power of creativity in healthcare PR

By Lisa Cave

Virtual Medical Education & Training – Engaging Your Advisors Creatively

Creatively engage with your advisors by transforming your medical education and HCP training! Discover how to creatively plan, develop, and execute engaging virtual events, speaker programs, and mentorship activities. Co-create...

Impetus Digital

- PMLiVE

Roche’s Evrysdi tablets granted EC approval to treat spinal muscular atrophy

The neuromuscular disease affects approximately one in every 10,000 babies worldwide

- PMLiVE

VML Health appoints Nick Bartlett as chief executive officer of EU hub

Bartlett most recently served as head of consulting at Uniphar Group

- PMLiVE

Essential agility in an era of change for medical affairs

By Drew Owen and Clare Middleton

- PMLiVE

How AI can humanise data and transform healthcare communications

By Jane Sneddon and Alex Muller

Upcoming report announcement

Cuttsy+Cuttsy and ISPEP highlight key patient insights in new clinical trials report

Explore how Cuttsy+Cuttsy and ISPEP are spotlighting patient engagement in clinical trials through a new global report.

Cuttsy + Cuttsy

- PMLiVE

Next-gen Medical Education Technologies to Keep an Eye on in 2025

Dive into 2025's cutting-edge medical education technologies like immersive training, interactive data visualization, and microlearning. Discover how to boost engagement and drive real HCP impact.

Impetus Digital

regeneron headquarters

Regeneron gains rights to Hansoh’s GLP-1/GIP receptor agonist in deal worth $2bn

The candidate is being evaluated in a phase 3 obesity trial and phase 2b diabetes study

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links